{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-23-005658","form_type":"8-K","ticker":"ABUS","cik":"0001447028","company_name":"Arbutus Biopharma Corp","filed_at":"2023-09-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.965330+00:00","generated_at":"2026-06-10T21:39:59.548320+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Arbutus discontinues AB-161 and coronavirus programs, focuses on HBV; cash runway extended to Q3 2025","bullets":["Discontinuing AB-161 (oral RNA destabilizer) due to pre-clinical toxicology finding; no safety issues in Phase 1 single doses.","Discontinuing coronavirus combination therapy (AB-343) due to unfavorable PK profile in IND-enabling studies.","Dosed first subject in Phase 1a/1b for oral PD-L1 inhibitor AB-101; preliminary data expected H1 2024.","Pipeline changes expected to extend cash runway through Q3 2025.","Ongoing LNP patent litigations against Moderna (claim construction hearing Feb 2024) and Pfizer/BioNTech."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-23-005658","json":"https://secwatch.observer/filing/0001171843-23-005658.json","markdown":"https://secwatch.observer/filing/0001171843-23-005658.md","text":"https://secwatch.observer/filing/0001171843-23-005658.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1447028/000117184323005658/0001171843-23-005658-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1447028/000117184323005658/f8k_091123.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T21:39:59.548320+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}